Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2018 3
2019 1
2020 1
2021 5
2022 4
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.
Roos I, Hughes S, McDonnell G, Malpas CB, Sharmin S, Boz C, Alroughani R, Ozakbas S, Buzzard K, Skibina O, van der Walt A, Butzkueven H, Lechner-Scott J, Kuhle J, Terzi M, Laureys G, Van Hijfte L, John N, Grammond P, Grand'Maison F, Soysal A, Jensen AV, Rasmussen PV, Svendsen KB, Barzinji I, Nielsen HH, Sejbæk T, Prakash S, Stilund MLM, Weglewski A, Issa NM, Kant M, Sellebjerg F, Gray O, Magyari M, Kalincik T; MSBase Study GroupDanish MS Registry Study Group. Roos I, et al. Among authors: kant m. JAMA Neurol. 2023 Aug 1;80(8):789-797. doi: 10.1001/jamaneurol.2023.1625. JAMA Neurol. 2023. PMID: 37307006
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.
Spelman T, Magyari M, Piehl F, Svenningsson A, Rasmussen PV, Kant M, Sellebjerg F, Joensen H, Hillert J, Lycke J. Spelman T, et al. Among authors: kant m. JAMA Neurol. 2021 Oct 1;78(10):1197-1204. doi: 10.1001/jamaneurol.2021.2738. JAMA Neurol. 2021. PMID: 34398221 Free PMC article.
Cannabis-Based Medicine for Neuropathic Pain and Spasticity-A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial.
Hansen JS, Gustavsen S, Roshanisefat H, Kant M, Biering-Sørensen F, Andersen C, Olsson A, Chow HH, Asgari N, Hansen JR, Nielsen HH, Hansen RM, Petersen T, Oturai AB, Sellebjerg F, Sædder EA, Kasch H, Rasmussen PV, Finnerup NB, Svendsen KB. Hansen JS, et al. Among authors: kant m. Pharmaceuticals (Basel). 2023 Jul 28;16(8):1079. doi: 10.3390/ph16081079. Pharmaceuticals (Basel). 2023. PMID: 37630995 Free PMC article.
Predictors of treatment switching in the Big Multiple Sclerosis Data Network.
Spelman T, Magyari M, Butzkueven H, Van Der Walt A, Vukusic S, Trojano M, Iaffaldano P, Horáková D, Drahota J, Pellegrini F, Hyde R, Duquette P, Lechner-Scott J, Sajedi SA, Lalive P, Shaygannejad V, Ozakbas S, Eichau S, Alroughani R, Terzi M, Girard M, Kalincik T, Grand'Maison F, Skibina O, Khoury SJ, Yamout B, Sa MJ, Gerlach O, Blanco Y, Karabudak R, Oreja-Guevara C, Altintas A, Hughes S, McCombe P, Ampapa R, de Gans K, McGuigan C, Soysal A, Prevost J, John N, Inshasi J, Stawiarz L, Manouchehrinia A, Forsberg L, Sellebjerg F, Glaser A, Pontieri L, Joensen H, Rasmussen PV, Sejbaek T, Poulsen MB, Christensen JR, Kant M, Stilund M, Mathiesen H, Hillert J; Big MS Data Network: a collaboration of the Czech MS Registry, the Danish MS Registry, Italian MS Registry, Swedish MS Registry, MSBase Study Group, and OFSEP. Spelman T, et al. Among authors: kant m. Front Neurol. 2023 Dec 22;14:1274194. doi: 10.3389/fneur.2023.1274194. eCollection 2023. Front Neurol. 2023. PMID: 38187157 Free PMC article.
Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study.
Roar M, Nielsen ARH, Berg JM, Sirakov G, Stilund M, Schäfer J, Ratzer R, Frederiksen J, Asgari N, Ashna SN, Jensen HB, Kant M, Theódorsdóttir Á, Illes Z, Sellebjerg F, Magyari M, Schlosser LM, Nordborg H, Wergeland S, Sejbaek T. Roar M, et al. Among authors: kant m. Mult Scler Relat Disord. 2023 Dec;80:105127. doi: 10.1016/j.msard.2023.105127. Epub 2023 Nov 5. Mult Scler Relat Disord. 2023. PMID: 37956521
Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study.
Pontieri L, Blinkenberg M, Bramow S, Papp V, Rasmussen PV, Kant M, Schäfer J, Mathiesen HK, Jensen MB, Sirakov G, Berg JM, Kopp TI, Joensen H, Sellebjerg F, Magyari M. Pontieri L, et al. Among authors: kant m. Eur J Neurol. 2022 Feb;29(2):496-504. doi: 10.1111/ene.15142. Epub 2021 Oct 26. Eur J Neurol. 2022. PMID: 34644452
Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES).
Riemenschneider M, Hvid LG, Ringgaard S, Nygaard MKE, Eskildsen SF, Gaemelke T, Magyari M, Jensen HB, Nielsen HH, Kant M, Falah M, Petersen T, Stenager E, Dalgas U. Riemenschneider M, et al. Among authors: kant m. Mult Scler. 2022 Sep;28(10):1620-1629. doi: 10.1177/13524585221079200. Epub 2022 Mar 16. Mult Scler. 2022. PMID: 35296183 Clinical Trial.
20 results